Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13598498 | 1.00 | SLC6A1 (0.59) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| SCHEMBL4673135 | 1.00 | SLC6A1 (0.59) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| Hydrochloric Acid SCHEMBL30493363 | 0.98 | SLC6A1 (0.57) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| Hydrochloric Acid SCHEMBL21224938 | 0.98 | SLC6A1 (0.57) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| Hydrochloric Acid SCHEMBL28798276 | 0.98 | SLC6A1 (0.57) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| Hydrochloric Acid SCHEMBL30493397 | 0.98 | SLC6A1 (0.57) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| Benzene SCHEMBL27525396 | 0.94 | SLC6A1 (0.58) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| SCHEMBL4020828 | 0.94 | SLC6A1 (0.52) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| Hydrochloric Acid SCHEMBL6380748 | 0.92 | SLC6A1 (0.50) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| Trifluoroacetic Acid SCHEMBL27732114 | 0.88 | SLC6A1 (0.51) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118910627-A | Method for electrochemically synthesizing methylene quinone compound | 西北师范大学 | 2024-11-08 | — | — | CN | claimed |
| CN-118109390-A | Application of 3-methyl piperidine formate in wound treatment | 上海市皮肤病医院 | 2024-05-31 | — | — | CN | claimed |
| CN-118078823-A | Application of 3-methyl piperidine formate in treating inflammatory dermatosis | 上海市皮肤病医院 | 2024-05-28 | — | — | CN | claimed |
| CN-114656348-A | Improved preparation method of methylene quinone compound | 西北师范大学 | 2022-06-24 | — | — | CN | claimed |
| CN-109705014-A | A kind of novel chiral oxidation amine ligand and preparation method thereof | 南开大学 | 2019-05-03 | — | — | CN | claimed |
| CN-106986789-A | Hydroquinone compound and preparation method thereof and the application in antitumor or immunological regulation | 中国人民解放军军事医学科学院生物医学分析中心 | 2017-07-28 | — | — | CN | claimed |
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| EP-1778712-B1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | Univ Virginia Patent Found (US) | 2013-01-30 | — | — | EP | claimed |
| US-8188063-B2 | A2A receptor agonists for the central nervous system; antiinflammatory agents; 2,7-disubstituted-5-amino-pyrazolo[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidines, mefloquine, 8-(3-chlorostyryl)caffeine, 3,7,8-trisubstituted-1-propargyl-xanthines; 2,5-disubstituted-7-amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-29 | — | — | US | claimed |
| US-8178509-B2 | Method to treat sickle cell disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | claimed |
| WO-2006015357-A2 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2006-02-09 | — | — | WO | claimed |
| US-20050261236-A1 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-24 | — | — | US | claimed |
| WO-2005107463-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATMENT OF DIABETIC NEPHROPATHY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-11-17 | — | — | WO | claimed |
| US-20050182018-A1 | Method to reduce inflammatory response in transplanted tissue | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-18 | — | — | US | claimed |
| EP-1496911-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-01-19 | — | — | EP | claimed |
| EP-1434782-A2 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | University of Virginia Patent Foundation (US) | 2004-07-07 | — | — | EP | claimed |
| WO-2003086408-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-10-23 | — | — | WO | claimed |
| US-20030186926-A1 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-02 | — | — | US | claimed |
| WO-2003029264-A2 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-04-10 | — | — | WO | claimed |
| US-5010077-A | Tranquilizers | A/S FERROSAN (DK) | 1991-04-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261236-A1 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | ADORA2A, ADORA3, PDE4A | SLC6A1 2771/4885SMN1; SMN2 3724/4885SLC6A11 2584/4885 |
| US-20050182018-A1 | Method to reduce inflammatory response in transplanted tissue | ADORA2A, PDE4A, PDE4B | SLC6A1 2841/4885SMN1; SMN2 3909/4885SLC6A11 3044/4885 |
| US-20030186926-A1 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | ADORA2A, ADORA1, ADORA3 | SLC6A1 1997/4885SMN1; SMN2 3514/4885SLC6A11 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.